share_log

Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance

SEC ·  May 2 19:13
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.